OrbiMed Advisors LLC

ORBIMED ADVISORS LLC

Orbimed Advisors is an investment company that was founded in 1989 with a vision to “invest across the spectrum of healthcare companies from venture capital start-ups to large multinational companies.” The company started with its first public equity fund in 1989 and would expand to offer long/short equity and private equity investments by 1993. The company would continue to grow and expand, opening its Mumbai and Shanghai offices in Asia in 2007 and beginning its international expansion. In 2010, Orbimed Advisors would expand to the Middle East, opening an office in Israel. The company would then launch its first health care royalties and credit opportunities fund in 2011 and another royalty opportunities fund in 2015. Orbimed Advisors currently has approximately $15 billion in total assets under management spread across 5 accounts, all of which are discretionary. While its number of accounts has remained relatively steady in recent years, its total assets under management has increased significantly, growing from $1.2 billion back in 2010 to over 10 times that amount today.

Holdings MV

3.00B

Last Updated

2026-01-12

Total Holdings

Tracker Performance

OrbiMed Advisors LLC

S&P 500

Total Return

+43.94%

Annualized Return

+90.00%

1 Day Change

+0.68%

Sharpe Ratio

3.05

Trade Updates

2026-01-12

Ticker

Name

01/12

Sell

3.56%

Fill Price --

3.53%

Ticker

Name

01/12

Sell

8.27%

Fill Price --

7.82%

Ticker

Name

01/12

Sell

2.73%

Fill Price --

0.00%

Ticker

Name

01/12

Buy

5.84%

Fill Price --

5.85%

Ticker

Name

01/12

Buy

6.95%

Fill Price --

6.96%

Ticker

Name

01/12

Buy

0.00%

Fill Price --

2.75%

Ticker

Name

01/12

Buy

5.55%

Fill Price --

6.08%

Ticker

Name

01/12

Sell

4.24%

Fill Price --

4.22%

Ticker

Name

01/12

Sell

11.46%

Fill Price --

11.36%

Ticker

Name

01/12

Buy

2.98%

Fill Price --

2.99%

Ticker

Name

01/12

Sell

3.31%

Fill Price --

3.24%

Ticker

Name

01/12

Buy

4.91%

Fill Price --

4.95%

Ticker

Name

01/12

Sell

9.96%

Fill Price --

9.40%

Ticker

Name

01/12

Sell

3.77%

Fill Price --

3.72%

Ticker

Name

01/12

Buy

2.91%

Fill Price --

2.95%

Ticker

Name

01/12

Buy

3.68%

Fill Price --

4.11%

Ticker

Name

01/12

Buy

2.78%

Fill Price --

3.17%

Ticker

Name

01/12

Sell

3.88%

Fill Price --

3.87%

Ticker

Name

01/12

Sell

4.99%

Fill Price --

4.57%

Ticker

Name

01/12

Buy

4.77%

Fill Price --

4.98%

Current Holdings

Medical Biology

102.81%

Symbol

P&L %

Position Size

Ticker

Name

+751.76%

3.34%

Ticker

Name

+343.38%

4.81%

Ticker

Name

+185.51%

4.46%

Ticker

Name

+113.17%

13.31%

Ticker

Name

+93.83%

4.05%

Ticker

Name

+73.33%

7.76%

Ticker

Name

+62.51%

2.94%

Ticker

Name

+55.13%

2.97%

Ticker

Name

+40.44%

3.36%

Ticker

Name

+34.24%

9.07%

Ticker

Name

+32.70%

6.39%

Ticker

Name

+25.78%

5.47%

Ticker

Name

+10.10%

4.75%

Ticker

Name

+7.53%

4.19%

Ticker

Name

+1.25%

2.81%

Ticker

Name

+1.18%

2.90%

Ticker

Name

-0.07%

2.83%

Ticker

Name

-3.15%

4.38%

Ticker

Name

-7.97%

3.76%

Ticker

Name

-15.62%

6.45%

Disclaimer

This simulated portfolio Tracker is based on holdings disclosed in institutional 13F filings. We select the top 20 holdings and construct a portfolio weighted by their relative proportions. Holdings beyond the top 20 are excluded, as their impact on the portfolio is minimal. Focusing on the top 20 enhances practicality and reflects the institution's stock-picking ability. The portfolio is periodically rebalanced to align with updated 13F filings. Note that 13F disclosures typically have a 45-day delay (e.g., Q2 2025 data is disclosed by mid-August). Users should consider this lag when tracking the portfolio, though institutional holdings are generally long-term, emphasizing strategic rationale behind changes. This portfolio is for illustrative purposes only and does not constitute investment advice. All investment decisions are the user's responsibility. Investing involves risks, including potential loss of principal. Past performance is not indicative of future results.